94 related articles for article (PubMed ID: 61998)
1. Nonspecific inhibition of tumor growth in vivo by admixed allogeneic tumor-sensitized lymphoid cells and identical inactivated allogeneic tumor cells.
Sendo F; Nakayama M; Gotohda E; Kobayashi
J Immunol; 1976 Oct; 117(4):1340-5. PubMed ID: 61998
[TBL] [Abstract][Full Text] [Related]
2. Nonspecific inhibition of in vivo tumor growth by allo-sensitized lymphocytes - requirement of radio-sensitive T-lymphocytes.
Sendo F
Hokkaido Igaku Zasshi; 1982 Jan; 57(1):27-35. PubMed ID: 6978834
[TBL] [Abstract][Full Text] [Related]
3. Effect of x-irradiation of recipients on in vivo neutralization of syngeneic tumors by spleen cells nonspecificially immunized with allogeneic tumors.
Nakayama M; Sendo F; Gotohda E; Kobayashi H
Gan; 1977 Aug; 68(4):509-12. PubMed ID: 80344
[TBL] [Abstract][Full Text] [Related]
4. Augmentation of specific cell-mediated immune responses to tumor cells in tumor-bearing rats pretreated wih the antileukemia drug busulfan.
Mizushima Y; Sendo F; Miyake T; Kobayashi H
J Natl Cancer Inst; 1981 Apr; 66(4):659-65. PubMed ID: 6939913
[TBL] [Abstract][Full Text] [Related]
5. Passive transfer of systemic tumor immunity with cells generated in vitro by a secondary immune response to a syngeneic rat gross virus-induced lymphoma.
Bernstein ID
J Immunol; 1977 Jan; 118(1):122-8. PubMed ID: 830744
[TBL] [Abstract][Full Text] [Related]
6. Enhancement of antitumor transplantation resistance in rats by appropriately timed administration of busulfan.
Mizushima Y; Sendo F; Takeichi N; Hosohawa M; Kobayashi H
Cancer Res; 1981 Jul; 41(7):2917-21. PubMed ID: 6454480
[TBL] [Abstract][Full Text] [Related]
7. Differing contribution of various effector cells in the elimination of syngeneic or allogeneic cells.
Matsumoto T; Himeno K; Mitani M; Mori K; Miake S; Nomoto K
J Clin Lab Immunol; 1986 Feb; 19(2):83-9. PubMed ID: 3083105
[TBL] [Abstract][Full Text] [Related]
8. Antibody-mediated suppression of grafted lymphoma. III. Evaluation of the role of thymic function, non-thymus-derived lymphocytes, macrophages, platelets, and polymorphonuclear leukocytes in syngeneic and allogeneic hosts.
Shin HS; Hayden M; Langley S; Kaliss N; Smith MR
J Immunol; 1975 Apr; 114(4):1255-63. PubMed ID: 1078832
[TBL] [Abstract][Full Text] [Related]
9. A tumor-specific cytotoxic and neutralizing factor in rats immunized with ascites hepatoma induced by azo dyes.
El-Asfahani AM; Mizuno D; Hashimoto Y; Ishidate M; Nishioka K
Gan; 1975 Feb; 66(1):11-9. PubMed ID: 168113
[TBL] [Abstract][Full Text] [Related]
10. Kinetics of thymus- and bone marrow-derived lymphocytes in rats during tumor growth.
Klobusická M; Kalafut F; Novotná L
Neoplasma; 1977; 24(6):583-93. PubMed ID: 339115
[TBL] [Abstract][Full Text] [Related]
11. Specific stimulatory and cytotoxic effects of lymphocytes sensitized in vitro to either alloantigens or tumor antigens.
Kall MA; Hellström I
J Immunol; 1975 Mar; 114(3):1083-8. PubMed ID: 1112984
[TBL] [Abstract][Full Text] [Related]
12. In vitro stimulation and inhibition of tumor cell growth mediated by different lymphoid cell populations.
Norbury KC
Cancer Res; 1977 May; 37(5):1408-15. PubMed ID: 66982
[TBL] [Abstract][Full Text] [Related]
13. Allogeneic cell therapy in murine B-cell leukemia (BCL1): 1. Alloimmune-mediated graft-versus-leukemia (GVL) effects induced by unmodified and in vitro rIL-2-activated bone marrow and lymphocytes from different lymphoid compartments.
Weiss L; Reich S; Slavin S
Cytokines Cell Mol Ther; 1999 Sep; 5(3):145-52. PubMed ID: 10641572
[TBL] [Abstract][Full Text] [Related]
14. Effect of thymectomy on tumor development and on T and B lymphocytes in tumor-bearing rats.
Klobusická M; Koníková E; Novotná L
Neoplasma; 1979; 26(4):413-21. PubMed ID: 392324
[TBL] [Abstract][Full Text] [Related]
15. [Immunogenicity of viable tumor cells--comparison of immunogenicity between xenogenized tumor cells and BCG-tumor cell vaccine].
Suzuki Y
Hokkaido Igaku Zasshi; 1985 Nov; 60(6):908-15. PubMed ID: 4085970
[TBL] [Abstract][Full Text] [Related]
16. Characterization of immunosuppressor cells in rats immunized with solubilized tumor-associated antigens prepared from a methylcholanthrene-induced fibrosarcoma.
Minami A; Kasai M; Mizushima Y; Takeichi N; Hosokawa M; Kobayashi H
Cancer Res; 1980 Jul; 40(7):2129-34. PubMed ID: 6446378
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of cell-mediated cytotoxicity against tumor-associated antigens by suppressor lymph node cells from mice bearing methylcholanthrene-induced sarcomas.
Indrová M; Bubeník J
Neoplasma; 1979; 26(4):405-12. PubMed ID: 160510
[TBL] [Abstract][Full Text] [Related]
18. Tumor-specific immune responsiveness of the tumor-bearing host.
Burk MW; Yu S; McKhann CF
Isr J Med Sci; 1976; 12(4-5):360-8. PubMed ID: 939694
[TBL] [Abstract][Full Text] [Related]
19. Studies of allogeneic tumor transplants: induced rejection of advanced tumors by immune alteration of recipients.
Russell PS; Chase CM; Burton RC
J Immunol; 1983 Feb; 130(2):951-7. PubMed ID: 6336775
[TBL] [Abstract][Full Text] [Related]
20. Essential requirement of I-A region-identical host bone marrow or bone marrow-derived cells for tumor neutralization by primed L3T4+ T cells.
Ozawa H; Iwaguchi T; Kataoka T
J Immunol; 1987 Dec; 139(11):3896-901. PubMed ID: 2960743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
